PCM
CALT

PenderFund Capital Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

PenderFund Capital Management’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,000
Closed -$320K – 154
2024
Q2 		$320K Buy
+6,000
New +$165K 0.09% 76

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

PenderFund Capital Management's CALT Position: Q3 2024 in Review

PenderFund Capital Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 6,000 shares — an estimated $320K sold.

PenderFund Capital Management first reported a position in CALT in Q2 2024 and held it in 1 quarter. The position peaked at $320K in Q2 2024. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • PenderFund Capital Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • PenderFund Capital Management sold 6,000 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $320K.
  • PenderFund Capital Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2024 and held it in 1 quarter.
  • PenderFund Capital Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $320K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on PenderFund Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.